Last reviewed 2026-04-20 · How we verify

BELINOSTAT

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nausea
• Fatigue
• Pyrexia
• Anemia
• Vomiting
• Constipation
• Diarrhea
• Dyspnea
• Rash
• Peripheral Edema
• Cough
• Thrombocytopenia

Serious adverse events

• Pneumonia
• Pyrexia
• Infection
• Anemia
• Increased Creatinine
• Thrombocytopenia
• Multi-organ Failure
• Hepatic Failure
• Tumor Lysis Syndrome
• Ventricular Fibrillation

Key clinical trials

• Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (PHASE2)
• Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment (PHASE1)
• A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity (PHASE2)
• Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma (PHASE3)
• Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (PHASE2)
• Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (PHASE1)
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (PHASE1)
• Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• BELINOSTAT CI brief — competitive landscape report
• BELINOSTAT updates RSS · CI watch RSS